In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Statistics Quarterly, Q1 2005

Executive Summary

In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

You may also be interested in...

Novartis/Hexal: Generic Consolidation, and More

Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.

Mid-Sized European M&A Fills Earnings Gap--And More?

Solvay's acquisition of France's Fournier suggests that there is value within Europe's family-owned, domestically-focused groups, and at good prices. The deal will boost Solvay's earnings until its own pipeline matures, although some question the potential for longer-term synergies.

Above and Below the Belt in Women's Health Care: Cytyc buys Proxima

Cytyc purchased Proxima Therapeutics, a brachytherapy company with a device to treat breast cancer, for $160 million in cash, following on its acquisition last year of Novacept, a manufacturer of a minimally-invasive endometrial ablation device to treat excessive menstrual bleeding. Three years earlier, Cytyc had acquired Pro-Duct Health, developer of a new test to assess the breast cancer risk of an at-risk patient. Cytyc is clearly going in the direction of creating an overall franchise in women's health, integrating diagnostics and therapeutics, both above and below the belt. But investors want to know that deals don't simply represent a piecemeal, opportunistic approach to business development, but that they fit together in a larger context. It's all about leveraging Cytyc's distribution channel in women's health, says CEO Patrick Sullivan.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts